Speed
139 days to first decision for reviewed manuscripts only
113 days to first decision for all manuscripts
205 days from submission to acceptance
39 days from acceptance to publication
Citation Impact
1.883 - 2-year Impact Factor
2.185 - 5-year Impact Factor
0.880 - Source Normalized Impact per Paper (SNIP)
0.980 - SCImago Journal Rank (SJR)
Usage
2,854,687 Downloads
8,868 Altmetric Mentions
A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial
The COVID-19 pandemic has imposed an enormous burden on health care systems around the world. In the past, the administration of convalescent plasma of patients having recovered from SARS and severe influenza ...
Citation: Trials 2020 21:981